Last updated 25 May 2018
We commit to ensuring the quality, safety and reliable supply of our products. If the supply of our medicines or vaccines is disrupted in Australia we will publish details here.
Due to high take up of flu vaccination in the last two months, reflecting the importance Australians are placing on helping protect themselves against serious illness, GSK’s supply of its influenza vaccine, Fluarix Tetra, for the 2018 influenza season has now been fully distributed within Australia. GSK is unable to manufacture any additional doses, however is working with Government to see if it is possible to access more doses from other countries.
All pre-ordered Fluarix Tetra doses for the 2018 season have now been delivered, including all doses provided to state governments to support state and federal vaccination programs. GSK has also delivered additional reserve doses it brought into the country at the start of the influenza season.
Menveo [Meningococcal (Groups A, C, W-135 and Y) Oligosaccharide CRM197 Conjugate Vaccine] is experiencing a supply constraint and is currently out of stock.
This supply constraint is due to manufacturing disruption combined with high demand. There is no impact on the safety or quality of the product. We expect the supply situation to normalise in 2019, and will provide the next update on supply of this vaccine in January 2019.
Havrix 720 Junior [inactivated hepatitis A virus vaccine] and Havrix 1440 Adult [inactivated hepatitis A virus vaccine] are experiencing supply constraints and are currently out of stock. We expect to provide the next update on supply of these vaccines in August 2018.
Please note, that the following GSK hepatitis A containing vaccines continue to be in stock and are not impacted by this supply constraint: Twinrix Adult [720/20] [combined hepatitis A and hepatitis B vaccine], Twinrix Junior [360/10] [combined hepatitis A and hepatitis B vaccine].
Engerix-B adult (hepatitis B surface antigen recombinant (yeast) vaccine)
This vaccine is experiencing intermittent supply constraints in Australia due to a disruption in the manufacturing process. Production is now back to normal, however it will take time to re-build capacity.
GSK prioritises hepatitis B vaccine availability for those most at risk of the disease and confirms uninterrupted supply of Engerix-B to all Australian State, Territory and Federal Government vaccination programs where Engerix-B is the vaccine of choice.
We understand this supply disruption may be distressing for those who are not covered by government programs and who may be required to vaccinate themselves for occupational reasons or because they are planning on travelling to hepatitis-affected areas.
Engerix-B paediatric (hepatitis B surface antigen recombinant (yeast) vaccine) continues to be available.
Please visit the TGA website for ongoing updates to supply.
For more information on GSK's medicines or vaccines, please contact GSK medical information on 1800 033 109.